Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huoitong Granule for Ischemic Stroke with Stable Coronary Heart Disease
ChiCTR2300076657Phase 4Not yet recruiting
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Feb 2023
- Countries
- 1
01
Overview
Phase 4, open-label trial of Huoitong Granule in ischemic stroke, coronary arteriosclerosis and Large Artery Atherosclerotic Stroke (2 cohorts), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoints: Major adverse cardiovascular events (MACE), Modified Rankin Scale (mRS) and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Huoitong Granule
03
Conditions
ischemic strokecoronary arteriosclerosisLarge Artery Atherosclerotic Stroke
Beyond the preview
Go deeper on ChiCTR2300076657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076657.